x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Decera Clinical Education Oncology Podcast

Decera Clinical Education

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

education courses

All Episodes

00:38:12

Expert Insight on Key Data From ASCO 2021 Informing...

Decera Clinical Education Oncology Podcast ·

2021/06/24

In this episode, David Scott Miller, MD, FACOG, FACS, and Melissa M. Hardesty, MD, MPH, provide expert perspectives on new data from ASCO 2021 presented for endometrial, ovarian, and cervical cancers regarding:Results from a pilot study of pembrolizumab monotherapy in patients with Lynch-like vs sporadic MLH1-methylated endometrial cancerUpdated analyses from the phase I GARNET trial, including data for patients with dMMR solid tumors (endometrial cancer and nonendometrial cancer cohorts)Final

en

00:21:31

Optimizing Therapy for Relapsed/Refractory Multiple...

Decera Clinical Education Oncology Podcast ·

2021/06/17

In this podcast episode, Suzanne Lentzsch, MD, PhD, and Saad Z. Usmani, MD, MBA, FACP, discuss how they select optimal treatment for relapsed/refractory (R/R) multiple myeloma (MM) and answer audience questions from a live webinar. Topics include:Selecting optimal triplet regimen after first relapseSequencing treatment options after multiple relapsesManaging patient expectations when selecting treatmentsEmerging treatment options for R/R MMPresenters: Suzanne Lentzsch, MD, PhDDirector, Multiple

en

00:27:05

Experts Answer FAQs on Biomarker-Driven Therapy for...

Decera Clinical Education Oncology Podcast ·

2021/05/19

In this episode, Nathan Pennell, MD, PhD; Jamie E. Chaft, MD; and Stephen V. Liu, MD, answer questions asked by an audience of healthcare professionals during a live CCO webinar on biomarker-driven therapies for NSCLC. Topics include:Choosing between immune checkpoint inhibitor monotherapy and combination therapy with an immune checkpoint inhibitor plus chemotherapy for newly diagnosed NSCLCIncorporating newly approved immunotherapies into practiceEvolving guidelines and recommendations for

en

00:24:34

Congress to Clinic: Post-ELCC Updates on...

Decera Clinical Education Oncology Podcast ·

2021/05/18

In this episode,Egbert F. Smit, MD, PhD; David Planchard, MD, PhD; and Helena A. Yu, MD, answer audience questions from a live webinar regarding clinical data on antibody–drug conjugates in NSCLC including:Biopsies and biomarker testing considerationsTumor heterogeneity and targeting of brain metastasesLiquid biopsiesSequencing of ADCs following previous therapyToxicity managementPresenters:Egbert F. Smit, MD, PhDProfessorDepartment of Pulmonary DiseasesLeiden University Medical CenterLeiden,

en

00:25:37

Immunotherapy for Advanced HCC: Case Series

Decera Clinical Education Oncology Podcast ·

2021/05/17

In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations key considerations for hepatologists, oncologists, and other healthcare professionals in the contemporary use of immune checkpoint inhibitors for treating specific case patients with advanced hepatocellular carcinoma, including:First-line systemic treatment for a patient with Child-Pugh A liver function and no elevated bleeding riskFirst-line systemic treatment for a patient with Child-Pugh A liver function and

en

00:25:45

Incorporating Immune Checkpoint Inhibitors Into...

Decera Clinical Education Oncology Podcast ·

2021/05/13

In this episode, Georgios Gakis, MD, and Mario Wolfgang Kramer, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in Germany. Topics include:Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapyResults from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapyWhen to consider first-line treatment with immune checkpoint

en

00:20:58

Managing Toxicities Associated With FGFR Inhibitors...

Decera Clinical Education Oncology Podcast ·

2021/05/04

In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss toxicities associated with FGFR inhibitors used in the treatment of urothelial cancer and other malignancies Presenters:Ignacio Durán, MD, PhDAssociate ProfessorGU Oncology Program LeaderDepartment of Medical OncologyHospital Universitario Marques de Valdecilla-IdivalSantander, SpainAlison Birtle, MD, FRCP, FRCRHonorary Senior LecturerFaculty of Health and MedicineUniversity of ManchesterManchester, United

en

00:15:38

Optimizing the Timing and Sequencing of Regorafenib...

Decera Clinical Education Oncology Podcast ·

2021/04/28

In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:Key data supporting the clinical use of these agentsOptimal sequencing and timing of useDosing considerationsKey adverse eventsPresenters:Joleen Hubbard, MDAssociate ProfessorGastrointestinal OncologistMedical OncologyMayo ClinicRochester, MinnesotaJohn L. Marshall, MDChief, Division of Hematology/OncologyDepartment of

en

00:31:59

Expert Answers to Questions on Contemporary...

Decera Clinical Education Oncology Podcast ·

2021/04/22

In this episode, Shaji K. Kumar, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD, and Jesús F. San-Miguel, MD, PhD, answer audience questions from a recent Clinical Care Options live webinar on managing multiple myeloma. Topics include:Approaches for managing smoldering multiple myelomaInsights on new strategies for managing newly diagnosed multiple myelomaIncorporating newly approved agents in the frontline and early relapse settingChoosing and sequencing BCMA-targeted

en

00:22:40

Combining PARP inhibitors With Other Treatments for...

Decera Clinical Education Oncology Podcast ·

2021/04/19

In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, consider the potential implications of ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:PARP inhibitors combined with androgen receptorsPhase III trials of PARP inhibitors with androgen receptor–directed therapyPARP inhibitors combined with immunotherapyPARP inhibitors and DNA damaging agentsPresenters:Karim Fizazi, MD, PhDFull ProfessorCancer

en

00:13:42

Rationale for Combining PARP Inhibitors With Other...

Decera Clinical Education Oncology Podcast ·

2021/04/15

In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the underlying rationale for using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:Possible synergy between PARP inhibitors and androgen receptor–directed therapyRationale for PARP inhibitors and immunotherapy combinationsBenefits and challenges of combining DNA damaging agents and PARP inhibitorPresenters:Karim Fizazi, MD, PhDFull ProfessorCancer MedicineInstitut Gustave

en

00:33:58

Expert Insight on Key Data From SGO 2021 Informing...

Decera Clinical Education Oncology Podcast ·

2021/04/06

In this episode, Jubilee Brown, MD, and Ursula Matulonis, MD, provide expert perspectives on new data from SGO 2021 presented for endometrial and ovarian cancer including:Results from KEYNOTE-775, a phase III trial of lenvatinib plus pembrolizumab in advanced endometrial cancerResults from the confirmatory phase III ARIEL4 evaluating rucaparib vs chemotherapy in BRCA-mutated relapsed ovarian cancer5-year follow-up from SOLO-1 trial of olaparib vs placebo in BRCA-mutated, newly diagnosed ovarian

en

00:10:51

Expert Answers to Questions on PARP Inhibition for...

Decera Clinical Education Oncology Podcast ·

2021/04/06

In this episode, Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including:Germline and somatic mutation testingManaging adverse events with PARP inhibitorsResistance to PARP inhibitorsImplications of monoallelic vs biallelic BRCA mutationsATM mutations and PARP inhibitor sensitivityPresenters:Charles J. Ryan, MDProfessor of MedicineB.J. Kennedy Chair in Clinical Medical

en

00:17:06

Expert Insights on Highlights From ASH 2020 on...

Decera Clinical Education Oncology Podcast ·

2021/03/26

In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including:Approved and Investigational Targeted Therapeutics for CLL Investigational CAR T-Cell Therapy for Indolent Lymphomas, CLL, and Mantle Cell LymphomaBispecific Antibodies and Other Investigational Targeted Agents for LymphomasTreatment for Older Patients With Hodgkin LymphomaPresenters:Jeremy S. Abramson, MD, MMScAssociate Professor

en

00:32:37

Improving Outcomes in EGFR-Mutated Non-Small-Cell...

Decera Clinical Education Oncology Podcast ·

2021/03/25

In this episode, Enriqueta Felip, MD, PhD, and Matthew Gubens, MD, MS, discuss evolving practice standards for EGFR-mutated non-small-cell lung cancer with topics including:Biomarker testing and strategiesOptimal first-line therapy in patients with NSCLCManagement of patients with CNS diseaseSelecting therapy for patients with noncanonical mutationsManagement strategies after progression on first-line EGFR TKI therapySelecting therapy for patients with early stage diseasePresenters: Enriqueta Felip,

en

00:20:18

Targeting FGFR in Urothelial Cancer and Beyond

Decera Clinical Education Oncology Podcast ·

2021/03/23

In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, interpret the latest clinical data on targeting FGFR in urothelial cancer Presenters:Ignacio Durán, MD, PhDAssociate ProfessorGU Oncology Program LeaderDepartment of Medical OncologyHospital Universitario Marques de Valdecilla-IdivalSantander, SpainAlison Birtle, MD, FRCP, FRCRHonorary Senior LecturerFaculty of Health and MedicineUniversity of ManchesterManchester, United KingdomConsultant OncologistRosemere Cancer

en

00:13:12

Expert Answers to HCP Questions on Pancreatic Cancer...

Decera Clinical Education Oncology Podcast ·

2021/03/22

In this episode, Michael J. Pishvaian, MD, PhD, and Rachna Shroff, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in pancreatic cancer treatment, with questions including:What is your preferred regimen for neoadjuvant therapy in patients with resectable disease?How do you sequence therapy for patients with metastatic pancreatic cancer?How can you manage a patient who develops significant diarrhea with FOLFIRINOX?Are cisplatin and

en

00:11:09

Expert Answers to HCP Questions on CAR T-Cell...

Decera Clinical Education Oncology Podcast ·

2021/03/18

In this episode, Frederick L. Locke, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with lymphomas, with questions including:How does the recent approval of lisocabtagene maraleucel and the expanded indication for axicabtagene ciloleucel add to the treatment landscape for DLBCL? Do you see CAR T-cell therapy ever being used in the first-line setting for DLBCL?How should physicians select patients for CAR T-cell

en

00:07:40

Frequently Asked Questions on Emerging Antibody–Drug...

Decera Clinical Education Oncology Podcast ·

2021/03/17

In this episode, D. Ross Camidge, MD, PhD, and Joel W. Neal, MD, PhD, answer questions on investigational antibody-drug conjugates for advanced NSCLC Presenters:Ross Camidge, MD, PhD Professor of Medicine/Oncology University of Colorado Cancer CenterAurora, ColoradoJoel W. Neal, MD, PhD Associate Professor of MedicineDivision of OncologyDepartment of MedicineStanford UniversityAttending PhysicianStanford Cancer InstitutePalo Alto, CaliforniaContent based on an online IME program supported by

en

00:11:43

Expert Answers to HCP Questions on CAR T-Cell...

Decera Clinical Education Oncology Podcast ·

2021/03/12

In this episode, Noopur Raje, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy, with questions including:Now that belantamab mafodotin is approved for relapsed/refractory multiple myeloma, what are your thoughts on how BCMA-directed CAR T-cell therapy might be sequenced? Is there reason to think CAR T-cell therapy would still be efficacious

en

224 results

Similar Podcasts

Science Talk

Albert Einstein College of Medicine

五分钟心理学

柠檬心理

Daily Facts

Amalia Dupray and Montgomery Jones.

Les dents et dodo

BFMTV

Veterinary Clinical Podcasts

The Royal Veterinary College